Clinical trial · Interventional
A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma
Phase 2/3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) Plus Bortezomib Comparing Three Doses of Tanespimycin in Patients With Relapsed-Refractory Multiple Myeloma
NCT00514371CI-TRIAL-00020083TIME-2completedPhase 2 / Phase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a phase 2/3, open label trial for patients with relapsed-refractory multiple myeloma. Study agent is tanespimycin (KOS-953), at three different dose levels in combination with a fixed dose of bortezomib.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bortezomib | Drug | Bortezomib | ALIAS |
| tanespimycin | Drug | Tanespimycin | ALIAS |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- tanespimycin and bortezomib
- description
- A patient will receive a standard dose of bortezomib followed by a high dose of tanespimycin.
- interventionNames
- Drug: tanespimycin
- Drug: Bortezomib
- type
- EXPERIMENTAL
- label
- bortezomib and tanespimycin
- description
- A patient will receive a standard dose of bortezomib followed by a mid dose of tanespimycin.
- interventionNames
- Drug: tanespimycin
- Drug: Bortezomib
- type
- EXPERIMENTAL
- label
- bortezomib tanespimycin
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Good performance status * Histologic evidence of multiple myeloma * Have had at least three prior treatment regimens for multiple myeloma that included both bortezomib and lenalidomide * No prior treatment with a heat shock 90 inhibitor or an investigational proteasome inhibitor * No known infections of HAV, HBV, HCV, or HIV * No chemotherapy, radiation therapy, or immune therapy for three weeks prior to enrollment.
References
Publications (0)
Data not yet available
No reference posted for this study.